Skip to main content
Premium Trial:

Request an Annual Quote

GE Healthcare Closes Whatman Buy, Adding Lab Technologies to Dx Portfolio

NEW YORK (GenomeWeb News) – General Electric’s GE Healthcare unit said today that it has closed its purchase of the lab filtration company Whatman.
 
GE Healthcare signed the £363 million ($713 million at the time) agreement to acquire Whatman in early February. 
 
Peter Ehrenheim, GE Healthcare’s president and CEO, said in a statement today that “combining the skills of the two companies will enable GE Healthcare to create strong added value for customers in biomedical and drug discovery research."
The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.